Diabetic foot ulcers (DFUs) are a common complication of diabetes, and with the increasing prevalence of diabetes across all markets, the number of patients suffering from DFUs is also expected to rise. Despite the availability of various treatment modalities, there are currently few advanced wound care products available to treat hard-to-heal chronic wounds. In addition, for the past 15 years, Regranex (becaplermin) has been the only pharmacologic wound-healing agent available; however, it is rarely used due a perceived lack of efficacy.

The DFU market is now set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years; Olympus Biotechs trafermin (recombinant human basic fibroblast growth factor), Macrocures CureXcell (activated leukocyte suspension), and Derma Sciences DSC127 (NorLeu3-A[1-7]). The first two topical antibacterials, Innocolls Cogenzia (gentamicin-collagen sponge) and Dipexium Pharmaceuticals Locilex (pexiganan acetate cream 1%), are also expected to launch in the US and the five major EU markets (5EU). Both pipeline agents offer an alternative way to treat infection by localizing an antibiotic directly at the wound site.

With the advent of these new product launches, the size of the DFU market is expected to grow substantially during the five-year forecast period.


[b]Scope[/b]

* Overview of DFUs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
* Annualized DFU therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012, and forecast to 2017Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications
* Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs
* Analysis of the current and future market competition in the global DFU therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


[b]Reasons to buy[/b]

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
* Develop business strategies by understanding the trends shaping and driving the global DFU therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DFU therapeutics market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Track drug sales in the global DFU therapeutics market from 2012-2017.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


[b]To order this report:[/b]

Email: [email protected]
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com


[b]RELATED LINK:[/b]
http://www.researchonglobalmarkets.com/opportunityanalyzer-diabetic-foot-ulcers-opportunity-analysis-and-forecast-to-2017.html